Loading
Acute Lymphoblastic Leukemia Research / Childhood Cancer Survivors' Quality of Life · Journal article
Journal of Adolescent and Young Adult Oncology · September 6, 2026
Reinforces what was already believed, rather than introducing something new.
This single-centre retrospective cohort of 1121 melanoma patients over 10 years confirms that Latin American adolescents and young adults (≤39 years) achieve better 5-year overall and event-free survival than middle-aged and elderly populations, with a hazard ratio of 1.93 for elderly versus AYA. The finding is robust to multivariate adjustment but is observational, single-site, and derived from a region where melanoma epidemiology may differ from other populations.
Single-centre retrospective cohort study. 1121 patients with melanoma stages I–IV diagnosed and treated at a single centre in Lima, Peru from 2010 to 2019. No specific eligibility criteria beyond histological diagnosis of melanoma stage I–IV are stated.. Intervention: Age group (≤39 years, 40–59 years, ≥60 years); observational stratification, not an intervention.. Compared with: Pairwise age-group comparisons: AYAs vs middle-aged, AYAs vs elderly, and middle-aged vs elderly.. n = 1,121. Single centre in Lima, Peru.
5-year OS rates: AYAs 52% vs middle-aged 43% vs elderly 32% (p < 0.01) 5-year EFS rates: AYAs 32% vs middle-aged 23% vs elderly 15% (p < 0.01) Hazard ratio for elderly (≥60 years) vs AYAs = 1.93, indicating worse prognosis with age
No comparison of treatment intensity or toxicity; adjuvant chemotherapy frequency differs by age but reasons and outcomes not detailed.
The data reinforce that young age is a favourable prognostic factor in melanoma and do not support treatment intensification in AYAs based on age alone. However, the high frequency of stage IV disease in AYAs (25.4%) signals a need for improved early detection strategies in primary care; clinicians should not assume that younger patients invariably present with earlier-stage disease.
Retrospective cohort study confirming that younger age predicts better melanoma survival; well-designed with adequate sample and long follow-up, but uses observational data and a single centre, limiting practice-changing impact.
As stated by the source record.
Quoted from the source exactly as published.
The data reinforce that young age is a favourable prognostic factor in melanoma and do not support treatment intensification in AYAs based on age alone. However, the high frequency of stage IV disease in AYAs (25.4%) signals a need for improved early detection strategies in primary care; clinicians should not assume that younger patients invariably present with earlier-stage disease.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Introduction: Outcomes among the Hispanic population are rarely explored in adolescents and young adults (AYAs). We aimed to compare sociodemographic, clinical, and survival outcomes of Latin American AYAs (≤39 years) with middle-aged (40–59 years) and older (≥60 years) patients with melanoma. Methods: A single-center retrospective cohort study among patients with melanoma stages I–IV was conducted in Lima, Peru, from 2010 to 2019. We evaluated overall survival (OS), event-free survival (EFS) rates, and prognostic factors. Results: Of 1121 patients with melanoma, 118 (10.5%) were AYAs, 357 (31.9%) were middle-aged, and 645 (57.6%) were elderly. Less frequencies of lower extremity as primary site (56.8%, 68.9%, and 82.3%, p < 0.01), ulceration (46.8%, 58.8%, 72.5%, p < 0.01), and acral histology (22.6%, and 32.8%, and 44.3%, p < 0.01) were present in AYAs. Moreover, AYAs had a higher frequency of American Joint Committee on Cancer stages I (16.1%, 10.1%, and 7.9%) and IV (25.4%, 24.6%, and 21.9%, p < 0.01). AYAs had less frequent adjuvant chemotherapy (10.3%, 18.4%, and 11.2%, p = 0.03). With a median follow-up of 9.8 years, the 5-year OS and EFS rates for AYAs (52%, 32%) were better than the middle-aged (43%, 23%) and older population (32%, 15%) ( p < 0.01). Multivariate analyses showed that AYAs had better prognosis than elderly population (≥60 years, hazard ratio = 1.93). Conclusions: Latin American AYAs with melanoma had less aggressive tumor characteristics and received less systemic therapy compared to middle-aged patients, yet demonstrated better EFS and OS rates across all age groups. Therefore, younger age is not a risk factor for worse survival outcomes. Given the relatively high frequency of stage IV disease in AYAs, it is crucial to develop strategies for early detection in the primary care setting.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.